HIT Consultant November 8, 2021
What You Should Know:
– Beacon Biosignals, a neurotechnology company applying artificial intelligence to EEG (electroencephalography) to unlock precision medicine for any condition affecting the brain, has announced an oversubscribed $27M Series A financing led by General Catalyst and with participation from Casdin Capital. This capital brings Beacon Biosignals’ total funding to date to $30M.
– Founded in 2019 by MD/PhDs and engineers from Harvard and MIT, Beacon’s launch was propelled by the vision of a computing platform designed to scale the interrogation of large brainwave datasets with unprecedented throughput and capability. Beacon Biosignals holds one of the world’s largest clinical EEG databases and couples that data with proprietary machine learning algorithms to identify neurobiomarkers associated with patient sub-types, drug...
Today's Sponsors
Today's Sponsor